期刊文献+

胸苷激酶1和Ki67在乳腺癌中的表达及其对预后的价值 被引量:1

Expression and prognostic significance of TK1 and Ki67 in breast cancer
原文传递
导出
摘要 目的探讨胸苷激酶1(TKl)、Ki67单独表达及联合表达对乳腺癌复发转移的影响。方法选取广州医学院第二附属医院乳腺外科2005年3月至2007年6月问手术切除的乳腺癌患者组织标本65例,均经病理证实。分为A、B两组,A组37例,为乳腺癌在5年内出现复发或转移者,B组28例,为无瘤生存超过5年者。分别测量A、B两组TK1及Ki67表达情况并描述生存曲线。结果TKlA组阳性率为91.8%,B组阳性率67.8%(x2=6.116,P=0.013),Ki67A组阳性率为78.4%,B组阳性率42.9%(X2=8.635,P=0.003)。A、B两组TKl和Ki67均呈阳性表达的比率分别为67.6%和39.3%(x2=5.159,P=0.023)。经Kaplan.Meier法生存曲线证实,与TK1和Ki67单独阳性表达者相比,联合阳性表达者的无瘤生存率显著降低,差异有统计学意义(x2=6.137,P=0.046)。结论TK1、Ki67均阳性表达是乳腺癌复发转移的高危因素,其预后较两者单独阳性表达者更差。 Objective To investigate the effects of the expressions of thymidine kinase 1 ( TK1 ) and Ki67 alone or their combination on the recurrence and metastasis of breast cancer. Methods Sixty-five sam- ples were selected from the Second Affiliated Hospital of Guangzhou Medical University from March 2005 to June 2007, which were resected by surgical operation and confirmed as breast carcinoma by pathology. They were individed into two groups including 37 cases with recurrence or metastasis in 5 years (group A), 28 cases without recurrence or metastasis in 5 years ( group B). The expressions of TK1 and Ki67 in the two groups were detected by immunohistochemical staining assay. Then, Kaplan-Meier assay was used to describe survival curve. Results The positive expression rate of TK1 in group A was 91.8%, which was dramatically higher than that in group B 67.8% (X2 = 6. 116, P =0.013). The positive expression rates of Ki67 in group A and B were 78.4% and 42.9% (X2 = 8. 635, P = 0.003). The positive expression rates of TK1 combined with Ki67 in group A and B were 67.6% and 39.3% (X2 = 5. 159, P = 0. 023 ). Moreover, disease free survival of patients with positive expression of TK1 combined with Ki67 decreased significantly, compared with patients with positive expression of TK1 or Ki67 alone (X2 = 6. 137, P = 0. 046). Conclusion Positive expression of TKt combined with Ki67 is the high risk factor of the reccurence or metastasis of breast carcinoma, and indi- cates poorer prognosis compared with positive expression alone.
出处 《国际肿瘤学杂志》 CAS 2013年第11期867-870,共4页 Journal of International Oncology
关键词 乳腺肿瘤 胸苷激酶 KI67 Breast neoplasms Thymidine kinase Ki67
  • 相关文献

参考文献15

  • 1Johnson LF, Rao LG, Muench AJ. Regulation of thymidine kinase enzyme level in serum-stimulated mouse 3T6 fibroblasts. Exp Cell Res, 1982,138( 1 ) :79-85.
  • 2Wu B J, Li WP, Qian C, et al. Increased serum level of thymidine kinase 1 correlates with metastatic site in patients with malignant mel- anoma. Tumour Biol, 2013,34(2) :643-648.
  • 3Mao Y, Wu J, Skog S, et al. Expression of cell proliferating genes in patients with non-small cell lung cancer by immunohistochemistry and cDNA profiling. Oncol Rep, 2005,13 ( 5 ) : 837-846.
  • 4Broet P, Romain S, Daver A, et al. Thymidine kinase as a prolifera- tive marker: clinical relevance in 1,692 primary breast cancer patients. J Clin Oncol, 2001,19 ( 11 ) :2778-2787.
  • 5李树玲.乳腺癌防治研究回顾与展望[J].国外医学(肿瘤学分册),2000,27(1):14-17. 被引量:39
  • 6He Q, Fornander T, Johansson H, et al. Thymidine kinase 1 in ser- um predicts increased risk of distant or loco-regional recurrence fol- lowing surgery in patients with early breast cancer. Anticancer Res, 2006,26(6C) :4753-4759.
  • 7Zhang J, Jia Q, Zou S, et al. Thymidine kinase 1 : a proliferation marker for determining prognosis and monitoring the surgical outcome of primary bladder carcinoma patients. Oncol Rep, 2006,15 (2) : 455-461.
  • 8Agarwal HK, McElroy CA, Sjuvarssan E, et al. Synthesis of N3-sub- stituted carboranyl thymidine bioconjugates and their evaluation as substrates of recombinant human thymidine kinase 1. Eur J Med Chem, 2013,60:456-468.
  • 9Huang ZH, Tian XS, Li R, et al. Elevated thymidine kinase 1 in ser- um following neoadjuvant chemotherapy predicts poor outcome for patients with locally advanced breast cancer. Exp Ther Med, 2012,3 (2) :331-335.
  • 10Liu Y, Ling Y, Qi Q, et al. Changes in serum thymidine kinase 1 levels during chemotherapy correlate with objective response in pa- tients with advanced gastric cancer. Exp Ther Med, 2011, 2 ( 6 ) : 1177-1181.

二级参考文献23

  • 1唐利立,张超杰,刘少华,毛杰,申郑堂,欧慧英,海健,邬玉辉,苑著.新辅助化疗对Ⅱ期和Ⅲ期乳腺癌的疗效观察[J].中国肿瘤临床,2005,32(22):1293-1295. 被引量:16
  • 2赵忠,张春辉,尤其邑,陈锦鹏.新辅助化疗对乳腺癌细胞周期的影响[J].交通医学,2007,21(2):121-122. 被引量:2
  • 3Sherley JL,Kelly TJ.Regulation of human thymidine kinase during the cell cyde[J].J Biol Chem,1988,263(17):8350-8358.
  • 4Coppock DL,Pardee AB.Control of thymidine kinase mRNA during the cell cycle[J].Mol Cell Biol,1987,7(8):2925-2932.
  • 5Broet P,Romain S,Darer A,et al.Thymidine kinase as a proliferative marker:clinical relevance in 1,692 primary breast cancer patients[J].J CAin Oncology,2001,19(11):2778-2787.
  • 6He Q Fornander T,Johansson H,et al.Thymidine kinase 1 in serum predicts increased risk of distant or loco-regional recurrence following surgery in patients with early breast cancer[J].Anticancer Res,2006,26(6C):4753-4759.
  • 7Tiezzi DG,Andrade JM,Ribeiro-Silva A,et al.HER-2,p53,p21 and hormonal receptors proteins expression as predictive factors of response and prognosis in locally advanced breast cancer treated with neoadjuvant docetaxel plus epirubicin combination[J].BMC Cancer,2007,7:36.
  • 8He Q Zhang P,Zou L,et al.Concentration of thymidine kinase 1 in serum (S-TK1) is a more sensitive proliferation marker in human solid tumors than its activity[J].Oncol Rep,2005,14.(4):1013-1019.
  • 9Romain S,Martin PM,Klijn JG,et al.DNA--synthesis enzyme activity:a biological tool useful for predicting anti-metabolic drug sengidvity in breast cancer[J].IntJ Cancer,1997,74(2):156-161.
  • 10Hutcheon AW,Heys SD,Sarkar TK,et al.Neoadjuvant docetaxel in locally advanced breast cancer[J].Breast Cancer Res Treat,2003,79Suppl 1:S19-S24.

共引文献46

同被引文献7

引证文献1

二级引证文献8

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部